Physician

Ajith Kuriakose, MD

According to 2025 Medicare claims, Ajith Kuriakose, MD (NPI: 1073772224) practices nephrology in the Beaumont-Port Arthur, TX market, with the plurality of this provider's patient population coming from Jefferson, TX. This provider's primary affiliated billing organization is BEAUMONT NEPHROLOGY ASSOCIATES (NPI: 1174639892; TIN: 742062554) and primary practice location at 77701-4680. Kuriakose is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Kuriakose's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,033 traditional Medicare patients, billed 5,786 HCPCS/CPT codes, and received $662,875 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 9,039 prescription claims across 1,494 beneficiaries totaling $568,684 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 105 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $255,268 to $662,875. Similarly, Part D prescription costs have risen steadily, from $61,137 to $568,684. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $542 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	523	2,944	$255,268
2016	760	3,942	$383,397
2017	790	4,523	$489,001
2018	706	4,701	$492,336
2019	857	5,656	$593,401
2020	967	6,429	$674,486
2021	1,125	6,358	$725,863
2022	1,119	6,551	$731,803
2023	1,066	5,844	$671,937
2024	1,033	5,786	$662,875

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	222	1,264	$61,137
2016	374	2,485	$347,225
2017	446	3,579	$747,821
2018	520	4,458	$441,400
2019	619	4,765	$397,714
2020	831	6,559	$440,363
2021	1,270	8,174	$555,467
2022	1,324	8,625	$674,070
2023	1,368	8,522	$750,654
2024	1,494	9,039	$568,684

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	35	$285
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	74	$1,751
2021	N/R	122	$3,737
2022	N/R	185	$6,081
2023	N/R	115	$4,005
2024	N/R	105	$4,020

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	128	986	$273
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	118	118	$116
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	131	183	$101
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	738	2,053	$89
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	206	1,690	$61

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	135	5,955	$104,935
Lokelma	Sodium Zirconium Cyclosilicate	73	2,577	$81,824
Sevelamer Carbonate	Sevelamer Carbonate	254	10,595	$70,211
Velphoro	Sucroferric Oxyhydroxide	21	604	$59,773
Renvela	Sevelamer Carbonate	11	430	$32,412

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7515	Cyclosporine, oral, 25 mg	N	N/R	20	$2,330
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	19	$800
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	24	$433
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	30	$364
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	12	$93

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Ajith Kuriakose, MD?

Tedicare shows public-source Medicare data for Ajith Kuriakose, MD (NPI 1073772224), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ajith Kuriakose, MD have ACO affiliation data?

Ajith Kuriakose, MD is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Ajith Kuriakose, MD?

Ajith Kuriakose, MD is linked to BEAUMONT NEPHROLOGY ASSOCIATES (billing NPI 1174639892) in the available physician profile data.

Does Ajith Kuriakose, MD have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.